| Year |
Citation |
Score |
| 2023 |
Shete N, Calabrese J, Tonetti DA. Revisiting Estrogen for the Treatment of Endocrine-Resistant Breast Cancer: Novel Therapeutic Approaches. Cancers. 15. PMID 37509308 DOI: 10.3390/cancers15143647 |
0.605 |
|
| 2022 |
Pal P, Millner A, Semina SE, Huggins RJ, Running L, Aga DS, Tonetti DA, Schiff R, Greene GL, Atilla-Gokcumen GE, Frasor J. Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells. Cancers. 14. PMID 35625985 DOI: 10.3390/cancers14102380 |
0.569 |
|
| 2021 |
Means-Powell JA, Mayer IA, Ismail-Khan R, Del Valle L, Tonetti D, Abramson VG, Sanders MS, Lush RM, Sorrentino C, Majumder S, Miele L. A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC). Clinical Breast Cancer. 22: 103-114. PMID 34903452 DOI: 10.1016/j.clbc.2021.10.013 |
0.538 |
|
| 2020 |
Abderrahman B, Maximov PY, Curpan RF, Fanning SW, Hanspal JS, Fan P, Foulds CE, Chen Y, Malovannaya A, Jain A, Xiong R, Greene GL, Tonetti DA, Thatcher GRJ, Jordan VC. Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics. PMID 33177154 DOI: 10.1158/1535-7163.MCT-20-0563 |
0.45 |
|
| 2020 |
Abderrahman B, Maximov PY, Curpan RF, Hanspal JS, Fan P, Xiong R, Tonetti DA, Thatcher GRJ, Jordan VC. Pharmacology and Molecular Mechanisms of Clinically-Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for Endocrine-Resistant Breast Cancer Treatment. Molecular Pharmacology. PMID 32788222 DOI: 10.1124/Molpharm.120.000054 |
0.61 |
|
| 2020 |
Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy. Breast Cancer Research and Treatment. PMID 32696319 DOI: 10.1007/S10549-020-05787-Z |
0.646 |
|
| 2020 |
Li Y, Zhao J, Gutgesell L, Shen Z, Ratia K, Dye K, Dubrovyskyii O, Zhao H, Huang F, Tonetti DA, Thatcher GR, Xiong R. Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib. Journal of Medicinal Chemistry. PMID 32453591 DOI: 10.1021/Acs.Jmedchem.0C00456 |
0.597 |
|
| 2020 |
Andreano KJ, Wardell SE, Baker JG, Desautels TK, Baldi R, Chao CA, Heetderks KA, Bae Y, Xiong R, Tonetti DA, Gutgesell LM, Zhao J, Sorrentino JA, Thompson DA, Bisi JE, et al. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment. PMID 32130619 DOI: 10.1007/S10549-020-05575-9 |
0.601 |
|
| 2020 |
O'Regan R, Hurley R, Sachdev J, Bleeker J, Tonetti D, Thatcher G, Venuti R, Dudek A. Abstract P5-11-06: Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine therapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-11-06 |
0.509 |
|
| 2019 |
Lu Y, Gutgesell L, Xiong R, Zhao J, Li Y, Rosales C, Hollas M, Shen Z, Gordon-Blake J, Dye K, Wang YT, Lee S, Chen H, He D, Dubrovyskyii O, ... ... Tonetti DA, et al. Design and Synthesis of Basic Selective Estrogen Receptor Degraders (B-SERDs) for Endocrine Therapy Resistant Breast Cancer. Journal of Medicinal Chemistry. PMID 31746603 DOI: 10.1021/Acs.Jmedchem.9B01580 |
0.585 |
|
| 2019 |
ORegan RM, Hurley R, Sachdev JC, Bleeker J, Tonetti D, Thatcher G, Venuti R, Dudek AZ. Abstract CT051: Phase I study of TTC-352 in patients with estrogen receptor-positive metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct051 |
0.45 |
|
| 2019 |
Xiong R, Li Y, Zhao J, Tonetti D, Thatcher G. Abstract 3830: Novel bromodomains and extra-terminal motif (BET) inhibitors developed against estrogen receptor positive, fulvestrant- and CDK4/6-resistant breast cancer models Cancer Research. 79: 3830-3830. DOI: 10.1158/1538-7445.Am2019-3830 |
0.669 |
|
| 2019 |
Xiong R, Li Y, Zhao J, Huang F, Shen Z, Lu Y, Gutgesell L, Tonetti D, Thatcher G. Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer Annals of Oncology. 30: v189. DOI: 10.1093/Annonc/Mdz244.064 |
0.606 |
|
| 2018 |
O'Regan R, Hurley R, Sachdev JC, Tonetti DA, Thatcher GR, Venuti RP, Dudek AZ. Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1108 |
0.604 |
|
| 2018 |
Gutgesell LM, Xiong R, Zhao J, Zhao H, Tonetti DA, Thatcher GR. Abstract 3744: Multiple endocrine-resistant breast cancer cell lines retain ER and sensitivity to endocrine therapy Endocrinology. 78: 3744-3744. DOI: 10.1158/1538-7445.Am2018-3744 |
0.568 |
|
| 2018 |
Rosales CI, Zhao J, Gutgesell LM, Xiong R, Tonetti DA, Thatcher GR. Abstract 3738: Three-dimensional treatment-resistant breast cancer spheroids as a predictive model of in vivo response to endocrine therapy Cancer Research. 78: 3738-3738. DOI: 10.1158/1538-7445.Am2018-3738 |
0.651 |
|
| 2017 |
Pham TND, Perez White BE, Zhao H, Mortazavi F, Tonetti DA. Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin. Bmc Cancer. 17: 832. PMID 29216867 DOI: 10.1186/S12885-017-3827-Y |
0.612 |
|
| 2017 |
White BP, Molloy ME, Zhao H, Zhang Y, Tonetti DA. Retraction Note to: Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Molecular Cancer. 16: 121. PMID 28716023 DOI: 10.1186/S12943-017-0697-5 |
0.653 |
|
| 2017 |
Xiong R, Zhao J, Gutgesell LM, Wang YT, Lee S, Karumudi B, Zhao H, Lu Y, Tonetti DA, Thatcher GR. Novel Selective Estrogen Receptor Downregulators (SERDs) Developed Against Treatment-Resistant Breast Cancer. Journal of Medicinal Chemistry. PMID 28117994 DOI: 10.1021/Acs.Jmedchem.6B01355 |
0.565 |
|
| 2017 |
Tonetti DA, Xiong R, Zhao J, Gutgesell L, Dudek AZ, Thatcher GR. Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E14090 |
0.65 |
|
| 2017 |
Gutgesell L, Xiong R, Thatcher G, Tonetti D. Abstract P3-04-23: Combination therapy of targeted anticancer pathways and estrogen receptor ligands and their responses inde novoandtamoxifen resistant cell models Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-04-23 |
0.599 |
|
| 2017 |
Gutgesell LM, Xiong R, Zhao J, Tonetti DA, Thatcher GR. Abstract 3603: Optimizing combination therapy against antiestrogen-resistance in estrogen receptor positive breast cancer Endocrinology. 77: 3603-3603. DOI: 10.1158/1538-7445.Am2017-3603 |
0.596 |
|
| 2016 |
Zhao H, Pham T, Emmadi R, Wiley E, Warso M, Perez-Tamayo A, Salti G, Hoskins K, Tonetti DA. Abstract B19: Breast cancer patient-derived xenografts: The University of Illinois at Chicago Cancer Center experience Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B19 |
0.577 |
|
| 2016 |
Xiong R, Zhao J, Gutgesell L, Tonetti D, Thatcher G. Abstract 3902: Novel selective estrogen receptor downregulators developed using endocrine-independent breast cancer cell lines Cancer Research. 76: 3902-3902. DOI: 10.1158/1538-7445.Am2016-3902 |
0.637 |
|
| 2015 |
Xiong R, Patel HK, Gutgesell LM, Zhao J, Delgado-Rivera L, Pham TN, Zhao H, Carlson KE, Martin TA, Katzenellenbogen JA, Moore TW, Tonetti D, Thatcher GR. Selective human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer. Journal of Medicinal Chemistry. PMID 26681208 DOI: 10.1021/Acs.Jmedchem.5B01276 |
0.676 |
|
| 2015 |
Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, Emmadi R, Kajdacsy-Balla A, Banerji N, McDonald W, Khan SA, Tonetti DA. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. Springerplus. 4: 710. PMID 26618099 DOI: 10.1186/S40064-015-1512-7 |
0.543 |
|
| 2015 |
Rauscher GH, Kresovich JK, Poulin M, Yan L, Macias V, Mahmoud AM, Al-Alem U, Kajdacsy-Balla A, Wiley EL, Tonetti D, Ehrlich M. Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation. Bmc Cancer. 15: 816. PMID 26510686 DOI: 10.1186/S12885-015-1777-9 |
0.446 |
|
| 2015 |
Thatcher GR, Xiong R, Patel HK, Zhao J, Liang X, Wang Y, Molloy ME, Tonetti D. Abstract P3-05-23: Novel, non-uterotrophic, selective estrogen mimics cause regression of tamoxifen-resistant breast cancer in 2D and 3D cultures and in mouse xenograft models Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-23 |
0.531 |
|
| 2015 |
Pham TN, Perez-White B, Tonetti DA. Abstract 4095: Protein kinase C alpha (PKCα) is a novel regulator of FOXC2 and p120-catenin in triple negative and endocrine resistant breast cancer Cancer Research. 75: 4095-4095. DOI: 10.1158/1538-7445.Am2015-4095 |
0.595 |
|
| 2015 |
Patel H, Xiong R, Gutgesell L, Zhao J, Molloy ME, Tonetti D, Thatcher GRJ. Abstract C98: Selective estrogen mimics (SEMs) for the treatment of tamoxifen resistant breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C98 |
0.694 |
|
| 2014 |
Weiss MS, Peñalver Bernabé B, Shin S, Asztalos S, Dubbury SJ, Mui MD, Bellis AD, Bluver D, Tonetti DA, Saez-Rodriguez J, Broadbelt LJ, Jeruss JS, Shea LD. Dynamic transcription factor activity and networks during ErbB2 breast oncogenesis and targeted therapy. Integrative Biology : Quantitative Biosciences From Nano to Macro. 6: 1170-82. PMID 25303361 DOI: 10.1039/C4Ib00086B |
0.494 |
|
| 2014 |
Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS, Cook RS. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. The Journal of Clinical Investigation. 124: 4737-52. PMID 25250573 DOI: 10.1172/Jci76375 |
0.472 |
|
| 2014 |
Molloy ME, White BE, Gherezghiher T, Michalsen BT, Xiong R, Patel H, Zhao H, Maximov PY, Jordan VC, Thatcher GR, Tonetti DA. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Molecular Cancer Therapeutics. 13: 2515-26. PMID 25205655 DOI: 10.1158/1535-7163.Mct-14-0319 |
0.605 |
|
| 2014 |
Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan SA, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget. 5: 6038-48. PMID 25153721 DOI: 10.18632/Oncotarget.2153 |
0.51 |
|
| 2014 |
Peng M, Emmadi R, Wang Z, Wiley EL, Gann PH, Khan S, Banerji N, McDonald W, Asztalos S, Pham TN, Tonetti DA, Tyner AL. PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget. PMID 25015012 DOI: 10.18632/oncotarget.2153 |
0.358 |
|
| 2014 |
Molloy ME, White BP, Zhao H, Michalsen BT, Patel HK, Zhao J, Xiong R, Siklos MI, Thatcher GRJ, Tonetti DA. Abstract 619: Selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer Cancer Research. 74: 619-619. DOI: 10.1158/1538-7445.Am2014-619 |
0.67 |
|
| 2014 |
Patel H, Xiong R, Zhao J, Molloy ME, Tonetti D, Thatcher GRJ. Abstract 2710: Lead based development and evaluation of selective estrogen mimics in tamoxifen resistant breast cancer Cancer Research. 74: 2710-2710. DOI: 10.1158/1538-7445.Am2014-2710 |
0.68 |
|
| 2014 |
Thatcher G, Xiong R, Patel H, Zhao J, Liang X, Wang Y, Molloy M, Tonetti D. 316 Potent, partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifen-resistant breast cancer European Journal of Cancer. 50: 103. DOI: 10.1016/S0959-8049(14)70442-3 |
0.634 |
|
| 2013 |
Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, ... ... Tonetti DA, et al. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2: e60. PMID 23917222 DOI: 10.1038/oncsis.2013.26 |
0.752 |
|
| 2013 |
Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, Macias V, Kajdacsy-Balla A, Tyner AL. PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Research. 73: 5426-37. PMID 23856248 DOI: 10.1158/0008-5472.Can-13-0443 |
0.384 |
|
| 2013 |
Perez White B, Molloy ME, Zhao H, Zhang Y, Tonetti DA. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer. Molecular Cancer. 12: 34. PMID 23634843 DOI: 10.1186/1476-4598-12-34 |
0.653 |
|
| 2013 |
Ho T, Asztalos S, Majumdar N, Arslan AD, Stampfer MR, Wiley EL, Khan SA, Banerji N, McDonald W, He X, Tonetti DA, Beck WT. Abstract 4380: Splicing factor SRSF3 knockdown-induced breast cancer cell growth suppression and apoptosis is partially reversed by Z-VAD-FMK and its expression correlates malignancy of breast cancer. Cancer Research. 73: 4380-4380. DOI: 10.1158/1538-7445.Am2013-4380 |
0.626 |
|
| 2013 |
Arslan AD, Asztalos S, Stampfer M, Tonetti D, He X, Beck WT. Abstract 3201: PTBP1 stability is increased in ovarian and breast cancer cell lines compared to matched controls. Cancer Research. 73: 3201-3201. DOI: 10.1158/1538-7445.Am2013-3201 |
0.582 |
|
| 2012 |
Tonetti DA, Gao W, Escarzaga D, Walters K, Szafran A, Coon JS. PKCα and ERβ Are Associated with Triple-Negative Breast Cancers in African American and Caucasian Patients. International Journal of Breast Cancer. 2012: 740353. PMID 22500240 DOI: 10.1155/2012/740353 |
0.51 |
|
| 2012 |
White BEP, Zhao H, Kundu M, Molloy ME, Tonetti DA. Abstract 4216: Protein kinase C ≤ overexpression is associated with loss of membrane-associated E-cadherin and β-catenin in T47D xenograft breast tumors Cancer Research. 72: 4216-4216. DOI: 10.1158/1538-7445.Am2012-4216 |
0.53 |
|
| 2012 |
Pham T, Asztalos S, Weiss, Shea L, Tonetti D. Abstract P6-04-24: Overexpression of protein kinase C alpha differentially activates transcription factors in T47D breast cancer cells in the presence of 17β-estradiol both in the 2D and 3D environments. Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-04-24 |
0.517 |
|
| 2011 |
Asztalos S, Gann PH, Nonn L, Balla AK, Macias V, Deaton RJ, Wiley EL, Tonetti DA. Abstract 3737: The effects of pregnancy on ERα and Her2/neu protein expression in the normal breast Cancer Research. 71: 3737-3737. DOI: 10.1158/1538-7445.Am2011-3737 |
0.567 |
|
| 2011 |
White BEP, Zhao H, Tonetti DA. Abstract 2339: Overexpression of PKCα in T47D breast cancer cells induces migration via p120-catenin transcriptional downregulation Cancer Research. 71: 2339-2339. DOI: 10.1158/1538-7445.Am2011-2339 |
0.608 |
|
| 2011 |
Kundu M, Zhang Y, Zhao H, Tonetti DA. Abstract 2301: E2-induced T47D:A18/PKCα tumor regression is accompanied by translocation of ERα to extranuclear sites in association with caveolin-1 Cancer Research. 71: 2301-2301. DOI: 10.1158/1538-7445.Am2011-2301 |
0.408 |
|
| 2011 |
Molloy ME, Tonetti DA. Abstract 2289: Potential role for Src kinase inhibitors in PKCα-overexpressing breast cancer Cancer Research. 71: 2289-2289. DOI: 10.1158/1538-7445.Am2011-2289 |
0.532 |
|
| 2010 |
Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimo AV, Tonetti DA, Gartel AL. Thiazole antibiotics against breast cancer. Cell Cycle (Georgetown, Tex.). 9: 1214-7. PMID 20410687 DOI: 10.4161/Cc.9.6.10955 |
0.657 |
|
| 2010 |
Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, Wiley EL, Tonetti DA. Gene expression patterns in the human breast after pregnancy. Cancer Prevention Research (Philadelphia, Pa.). 3: 301-11. PMID 20179293 DOI: 10.1158/1940-6207.Capr-09-0069 |
0.525 |
|
| 2010 |
Han H, Frasor J, Tonetti D. Abstract 4608: Overexpression of PKCα alters gene expression pattern in T47D breast cancer cells associated with hormone-independent growth and tamoxifen resistance Endocrinology. 70: 4608-4608. DOI: 10.1158/1538-7445.Am10-4608 |
0.594 |
|
| 2009 |
Zhang Y, Zhao H, Asztalos S, Chisamore M, Sitabkhan Y, Tonetti DA. Estradiol-induced regression in T47D:A18/PKCalpha tumors requires the estrogen receptor and interaction with the extracellular matrix. Molecular Cancer Research : McR. 7: 498-510. PMID 19372579 DOI: 10.1158/1541-7786.Mcr-08-0415 |
0.504 |
|
| 2009 |
Asztalos S, Gann P, Hayes M, Nonn L, Beam C, Wiley E, Tonetti D. Role of lobular involution in pregnancy-associated breast cancer. Cancer Research. 69: 5038. DOI: 10.1158/0008-5472.Sabcs-5038 |
0.557 |
|
| 2009 |
White BP, Tonetti D. T47D/PKCα Cells Are Nonmigratory and NoninvasiveIn VitroDespite Tamoxifen ResistanceIn Vivo. Cancer Research. 69: 6173-6173. DOI: 10.1158/0008-5472.Sabcs-09-6173 |
0.477 |
|
| 2009 |
Asztalos S, Gann P, Hayes M, Nonn L, Wiley E, Khan S, Susnik B, Diaz L, Banerji N, Tonetti D. Increased Expression of Inflammatory Genes in Pregnancy-Associated Breast Cancers. Cancer Research. 69: 5158-5158. DOI: 10.1158/0008-5472.Sabcs-09-5158 |
0.58 |
|
| 2009 |
Molloy M, Thatcher G, Bolton J, Tonetti D. 2-(4-Hydroxyphenyl)-Benzo[b]thiophen-6-ol, an Estrogen-Like Compound, Induces Apoptosis in T47D/PKCα Breast Cancer Cells. Cancer Research. 69: 5140-5140. DOI: 10.1158/0008-5472.Sabcs-09-5140 |
0.583 |
|
| 2009 |
Kundu M, Zhang Y, Zhao H, Tonetti D. Estradiol Induced Regression of T47D:A18/PKCα Tumor Involves Translocation of Estrogen Receptor alpha from the Nucleus to the Cytoplasm. Cancer Research. 69: 4140-4140. DOI: 10.1158/0008-5472.Sabcs-09-4140 |
0.415 |
|
| 2008 |
Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, ... ... Tonetti DA, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research. 68: 5226-35. PMID 18593923 DOI: 10.1158/0008-5472.Can-07-5744 |
0.743 |
|
| 2008 |
Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, ... ... Tonetti DA, et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches (Cancer Research (July 1, 2008) 68 (5226-5235)) Cancer Research. 68: 7246. DOI: 10.1158/0008-5472.Can-68-17-Cor1 |
0.722 |
|
| 2008 |
Miele L, Rizzo P, Osipo C, Foreman K, Bocchetta M, Tonetti D. 6 INVITED Notch as a potential therapeutic target in cancer European Journal of Cancer Supplements. 6: 4. DOI: 10.1016/S1359-6349(08)71938-4 |
0.416 |
|
| 2007 |
Tonetti DA, Zhang Y, Zhao H, Lim SB, Constantinou AI. The effect of the phytoestrogens genistein, daidzein, and equol on the growth of tamoxifen-resistant T47D/PKC alpha. Nutrition and Cancer. 58: 222-9. PMID 17640169 DOI: 10.1080/01635580701328545 |
0.485 |
|
| 2006 |
Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis. 27: 1538-46. PMID 16513679 DOI: 10.1093/carcin/bgl002 |
0.381 |
|
| 2005 |
Constantinou AI, White BE, Tonetti D, Yang Y, Liang W, Li W, van Breemen RB. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. European Journal of Cancer (Oxford, England : 1990). 41: 647-54. PMID 15737570 DOI: 10.1016/J.Ejca.2004.12.005 |
0.32 |
|
| 2005 |
Peng X, Mehta RG, Tonetti DA, Christov K. Identification of novel RARbeta2 transcript variants with short 5'-UTRs in normal and cancerous breast epithelial cells. Oncogene. 24: 1296-301. PMID 15558014 DOI: 10.1038/Sj.Onc.1208284 |
0.509 |
|
| 2004 |
Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Research. 64: 1247-51. PMID 14973083 DOI: 10.1158/0008-5472.Can-03-3583 |
0.535 |
|
| 2004 |
Tonetti DA. Prevention of breast cancer by recapitulation of pregnancy hormone levels. Breast Cancer Research : Bcr. 6: E8. PMID 14680493 DOI: 10.1186/Bcr750 |
0.639 |
|
| 2003 |
Tonetti DA, Rubenstein R, DeLeon M, Zhao H, Pappas SG, Bentrem DJ, Chen B, Constantinou A, Craig Jordan V. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 87: 47-55. PMID 14630090 DOI: 10.1016/J.Jsbmb.2003.07.003 |
0.54 |
|
| 2003 |
Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chemical Research in Toxicology. 16: 832-7. PMID 12870885 DOI: 10.1021/Tx030004S |
0.58 |
|
| 2003 |
Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S. Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure. British Journal of Cancer. 88: 1400-1402. PMID 12778068 DOI: 10.1038/Sj.Bjc.6600923 |
0.442 |
|
| 2001 |
Fournier DB, Chisamore M, Lurain JR, Rademaker AW, Jordan VC, Tonetti DA. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer. Gynecologic Oncology. 81: 366-72. PMID 11371124 DOI: 10.1006/Gyno.2001.6164 |
0.63 |
|
| 2000 |
Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines British Journal of Cancer. 83: 782-791. PMID 10952784 DOI: 10.1054/Bjoc.2000.1326 |
0.537 |
|
| 1999 |
Tonetti DA, Jordan VC. The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens. Journal of Mammary Gland Biology and Neoplasia. 4: 401-13. PMID 10705923 DOI: 10.1023/A:1018722502034 |
0.636 |
|
| 1998 |
Tonetti DA, O'Regan R, Tanjore S, England G, Jordan VC. Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations. The Journal of Steroid Biochemistry and Molecular Biology. 65: 181-9. PMID 9699872 DOI: 10.1016/S0960-0760(98)00011-9 |
0.599 |
|
| 1998 |
Levenson AS, Tonetti DA, Jordan VC. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. British Journal of Cancer. 77: 1812-9. PMID 9667651 DOI: 10.1038/Bjc.1998.301 |
0.463 |
|
| 1997 |
Jordan VC, MacGregor JI, Tonetti DA. Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy. Clinical Oncology. 9: 390-394. PMID 9448968 DOI: 10.1016/S0936-6555(97)80134-3 |
0.523 |
|
| 1997 |
Tonetti DA, Jordan VC. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 62: 119-28. PMID 9393947 DOI: 10.1016/S0960-0760(97)00034-4 |
0.632 |
|
| 1997 |
Jordan VC, MacGregor JI, Tonetti DA. Tamoxifen: From breast cancer therapy to the design of a postmenopausal prevention maintenance therapy Osteoporosis International. 7: 52-57. PMID 9205647 DOI: 10.1007/Bf01674814 |
0.523 |
|
| 1996 |
Tonetti DA, Jordan VC. Targeted anti-estrogens to treat and prevent diseases in women Molecular Medicine Today. 2: 218-223. PMID 8796891 DOI: 10.1016/1357-4310(96)88775-2 |
0.538 |
|
| 1995 |
Tonetti DA, Jordan VC. Possible mechanisms in the emergence of tamoxifen-resistant breast cancer. Anti-Cancer Drugs. 6: 498-507. PMID 7579553 DOI: 10.1097/00001813-199508000-00002 |
0.567 |
|
| Show low-probability matches. |